Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atuliflapon in moderate-to-severe uncontrolled asthma
NL-OMON53653Phase 2Recruiting
- Sponsor
- AstraZeneca
- Start
- Dec 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in asthma comparing Atuliflapon with Placebo (2 arms). Primary endpoint: Time to first CompEx Asthma event. Started Dec 2023; status: recruiting.
02
Drugs
atuliflapon
03
Conditions
asthma
Beyond the preview
Go deeper on NL-OMON53653.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON53653.